Article thumbnail

Gene signatures of breast cancer progression and metastasis

By David I Rodenhiser, Joseph D Andrews, Theodore A Vandenberg and Ann F Chambers


Breast cancer is a heterogeneous disease. Patient outcome varies significantly, depending on prognostic features of patients and their tumors, including patient age, menopausal status, tumor size and histology, nodal status, and so on. Response to treatment also depends on a series of predictive factors, such as hormone receptor and HER2 status. Current treatment guidelines use these features to determine treatment. However, these guidelines are imperfect, and do not always predict response to treatment or survival. Evolving technologies are permitting increasingly large amounts of molecular data to be obtained from tumors, which may enable more personalized treatment decisions to be made. The challenge is to learn what information leads to improved prognostic accuracy and treatment outcome for individual patients

Topics: Review
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. A deep catalog of human genetic variation
  2. (2002). A gene-expression signature as a predictor of survival in breast cancer.
  3. (2003). A multigenic program mediating breast cancer metastasis to bone. Cancer Cell
  4. (2010). Abdulkarim B: The between biological subtype and locoregional recurrence in newly diagnosed breast cancer. Breast Cancer Res Treat
  5. (2007). Adjuvant chemotherapy - yes or no? Prognostic markers in early breast cancer. Ann Oncol
  6. (2010). Alcohol consumption and breast cancer recurrence and survival among women with early-stage breast cancer: The Life After Cancer Epidemiology study.
  7. (2010). Altman DG: Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines.
  8. (2008). Argani P: Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res
  9. (2009). Badve S: Breast cancer stem cells and intrinsic subtypes: controversies rage on. Curr Stem Cell Res Ther
  10. Breast cancer, local-regional and adjuvant therapy:
  11. (2008). Cancer stem cells: implications for the progression and treatment of metastatic disease.
  12. (2008). Chambers AF: Epigenetic mapping and functional analysis in a breast cancer metastasis model using whole-genome promoter tiling microarrays. Breast Cancer Res
  13. (2010). Chia SK: What is the diff erence between triple-negative and basal breast cancers? Cancer J
  14. (2004). Chlebowski RT: Discordance in estrogen (ER) and progestin receptor (PR) status between primary metastatic breast cancer: a metaanalysis. J Clin Oncol (Meeting Abstracts)
  15. (2009). Clemons MJ: Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer. Anticancer Res
  16. (2009). Clemons MJ: Does confi rmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol
  17. Cold S: Eff ect of obesity on prognosis after early breast cancer. Presented at San Antonio Breast Cancer Symposium, Thursday,
  18. (2010). Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res
  19. (2002). DR: Suppression of human melanoma metastasis by the metastasis suppressor gene, BRMS1. Exp Cell Res
  20. (2001). Eystein Lønning P, Børresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.
  21. (2003). FL: Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am
  22. (2005). Foekens JA: Gene-expression profi les to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet
  23. (2005). Gelmon KA: Population-based validation of the prognostic model ADJUVANT! for early breast cancer.
  24. (2005). Gene expression profi ling of breast cancer: a tumor marker.
  25. (2005). Genes that mediate breast cancer metastasis to lung. Nature
  26. (2009). Giuliano AE: Impact of micrometastases in the sentinel node of patients with invasive breast cancer.
  27. (2005). GM: Reporting recommendations for tumor marker prognostic studies.
  28. (2008). Goldhirsch A; International Breast Cancer Study Group: Distinct clinical and prognostic features of infi ltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials.
  29. (2009). Goldhirsch A: Clinical relevance of HER2 overexpression/amplifi cation in patients with small tumor size and node-negative breast cancer.
  30. (2009). Gonzalez-Angulo AM: Prognostic impact of discordance between triplereceptor measurements in primary and recurrent breast cancer. Ann Oncol
  31. (2009). Hershman DL: Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group.
  32. (2009). HJ: Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol
  33. (2003). HL: Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nat Rev Cancer
  34. (2008). Hortobagyi GN: Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist
  35. (2009). Hortobagyi GN: High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller.
  36. JE: Effi cacy of neoadjuvant Cisplatin in triple-negative breast cancer.
  37. (1999). Jr: Histologic features predict local recurrence after breast conserving therapy of phyllodes tumors. Breast Cancer Res Treat
  38. (2008). KL: Young age at diagnosis correlates with worse prognosis and defi nes a subset of breast cancers with shared patterns of gene expression.
  39. (2010). Kluger Y: Benefi ts of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic models. Breast Cancer Res
  40. Management of breast cancer with targeted agents: importance of heterogeneity.
  41. (2010). Mauriac L: Neoadjuvant chemotherapy: are we barking up the right tree? Ann Oncol
  42. (2000). Molecular portraits of human breast tumours. Nature
  43. (2010). Multi-platform whole-genome microarray analyses refi ne the epigenetic signature of breast cancer metastasis with gene expression and copy number. PLoS One
  44. (2009). Next-generation sequencing: from basic research to diagnostics. Clin Chem
  45. (2010). Next-generation sequencing. Breast Cancer Res 2009, 11 Suppl Rodenhiser et al. Breast Cancer Research 2011, 13:201 Page 7 of 870. Walsh
  46. (2001). Pantel K: ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients. Cancer Res
  47. (2010). Pantel K: HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res Treat
  48. (2003). Pantel K: Molecular signature associated with bone marrow micrometastasis in human breast cancer. Cancer Res
  49. (2007). PB: Diff erential expression of hypoxia and (lymph)angiogenesis-related genes at diff erent metastatic sites in breast cancer. Clin Exp Metastasis
  50. (2010). PH: Hormone receptor and c-ERBB2 status in distant metastatic and locally recurrent breast cancer. Pathologic correlations and clinical signifi cance.
  51. (2008). Piccart-Gebhart MJ: Clinical application of the 70-gene profi le: the MINDACT trial.
  52. (2010). Polyak K: Tumor heterogeneity: causes and consequences. Biochim Biophys Acta
  53. (2010). Potential biologic causes of the racial survival disparity in adjuvant trials of ER positive breast cancer.
  54. (2005). Reduced metastasis-suppressor gene mRNA-expression in breast cancer brain metastases.
  55. Release: NHGRI Seeks DNA Sequencing Technologies Fit for Routine Laboratory and Medical Use []
  56. (1984). RP: Dynamic heterogeneity and metastasis.
  57. (2009). S: HER-2/neu expression in primary and metastatic breast cancer. Breast Cancer Res Treat
  58. (2009). S: Mutational evolution in a lobular breast tumour profi led at single nucleotide resolution. Nature
  59. (2000). Schnitt SJ: Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med
  60. (2009). Sensitivity to input variability of the Adjuvant! Online breast cancer prognostic model.
  61. (2009). Steeg PS: Analyses of resected human brain metastases of breast cancer reveal the association between up-regulation of hexokinase 2 and poor prognosis. Mol Cancer Res
  62. (2005). Taback B: Distinct hypermethylation profi le of primary breast cancer is associated with sentinel lymph node metastasis. Clin Cancer Res
  63. (2009). Tjan-Heijnen VC: Micrometastases or isolated tumor cells and the outcome of breast cancer.
  64. (2006). TRANSBIG consortium: Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat Clin Pract Oncol
  65. (2007). Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res
  66. (1999). Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas.
  67. (2007). update of recommendations for the use of tumor markers in breast cancer.
  68. (2009). van’t Veer L: Prediction of adjuvant chemotherapy benefi t in endocrine responsive, early breast cancer using multigene assays. Breast
  69. (2005). Van’t Veer LJ: Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res
  70. (2007). Viale G: International Web-based consultation on priorities for translational breast cancer research. Breast Cancer Res
  71. (1987). WL: Human breast cancer: correlation of relapse and survival with amplifi cation of the HER-2/neu oncogene. Science
  72. (2004). Wolmark N: A assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.